We aimed to identify an existing inhibitor that has been proved to be effective at reducing CDYL-mediated chemoresistance in SCLC in clinical studies, and the EZH2 inhibitor GSK126 ultimately met the requirements. Here, EZH2 is linked to small cell lung carcinoma.